AxoGen
ISIN US05463X1063
|WKN A1JMHK
Market cap (in EUR)
630.53 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
Healthcare Healthcare Equipment Other Medical Devices United States
Financials
Key metrics
| Market capitalisation, EUR | 630.53 m |
| EPS, EUR | -0.21 |
| P/B ratio | 6.87 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 173.19 m |
| Net income, EUR | -9.21 m |
| Profit margin | -5.32% |
What ETF is AxoGen in?
There are 7 ETFs which contain AxoGen. All of these ETFs are listed in the table below. The ETF with the largest weighting of AxoGen is the L&G Healthcare Breakthrough UCITS ETF USD Acc.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
